BioCentury
ARTICLE | Clinical News

Jatenzo testosterone undecanoate: Phase III started

May 30, 2016 7:00 AM UTC

Clarus began the open-label, U.S. Phase III inTUne trial to compare 237 mg oral Jatenzo twice daily vs. 60 mg topical Axiron testosterone once daily for 105 days in about 180 patients. Patients may r...